2-chloro-N-isobutylpyrimidin-4-amine | 1201176-19-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-chloro-N-isobutylpyrimidin-4-amine
• 英文别名: (2-chloro-pyrimidin-4-yl)-isobutyl-amine；2-chloro-N-(2-methylpropyl)pyrimidin-4-amine
• CAS: 1201176-19-3
• 化学式: C₈H₁₂ClN₃
• 分子量: 185.656
• InChiKey: SRGUAFATGSDDEC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-chloro-N-isobutylpyrimidin-4-amine 在 palladium diacetate 、 sodium hydride 、 caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 生成 (S)-N-isobutyl-N-(2-(1-phenylethylamino)pyrimidin-4-yl)-2,3-dihydrobenzofuran-5-carboxamide
  参考文献：
  名称：

  Amide-based inhibitors of p38α MAP kinase. Part 2: Design, synthesis and SAR of potent N-pyrimidyl amides

  摘要：

  Optimization of a tri-substituted N-pyridyl amide led to the discovery of a new class of potent N-pyrimidyl amide based p38 alpha MAP kinase inhibitors. Initial SAR studies led to the identification of 5-dihydrofuran as an optimal hydrophobic group. Additional side chain modi. cations resulted in the introduction of hydrogen bond interactions. Through extensive SAR studies, analogs bearing free amino groups and alternatives to the parent (S)-alpha-methyl benzyl moiety were identified. These compounds exhibited improved cellular activities and maintained balance between p38a and CYP3A4 inhibition. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.02.090
• 作为产物：
  描述：

  2,4-二氯嘧啶 、 异丁胺 以 乙醇 为溶剂， 生成 2-chloro-N-isobutylpyrimidin-4-amine
  参考文献：
  名称：

  Discovery of novel analogs of KHS101 as transforming acidic coiled coil containing protein 3 (TACC3) inhibitors for the treatment of glioblastoma

  摘要：

  DOI：

  10.1016/j.ejmech.2022.114874

文献信息

• [EN] DIAMINO-PYRIDINE, PYRIMIDINE, AND PYRIDAZINE MODULATORS OF THE HISTAMINE H4 RECEPTOR<br/>[FR] MODULATEURS DE DIAMINO-PYRIDINE, PYRIMIDINE ET PYRIDAZINE DU RÉCEPTEUR DE L'HISTAMINE H4
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2009152325A1

  公开（公告）日：2009-12-17

  Diamino-pyridine, pyrimidine and pyridazine compounds which may be used as H4 receptor modulators, and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.

  二氨基吡啶、嘧啶和吡啉类化合物可用作H4受体调节剂，用于药物组合物和治疗H4受体活性介导的疾病状态、疾病和症状的方法，如过敏、哮喘、自身免疫疾病和瘙痒症。
• Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor
  申请人：Cai Hui

  公开号：US20110092474A1

  公开（公告）日：2011-04-21

  Diamino-pyridine, pyrimidine and pyridazine compounds which may be used as H 4 receptor modulators, and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H 4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.

  Diamino-pyridine，嘧啶和吡啶嗪化合物可用作H4受体调节剂，以及用于治疗由H4受体活性介导的疾病状态，紊乱和条件的制药组合物和方法，例如过敏，哮喘，自身免疫疾病和瘙痒症。
• Diamino-Pyridine, Pyrimidine, and Pyrazine Modulators of the Histamine H4 Receptor
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US20140357614A1

  公开（公告）日：2014-12-04

  Diamino-pyridine, pyrimidine and pyridazine compounds which may be used as H 4 receptor modulators, and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H 4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.

  Diamino-pyridine、嘧啶和吡啶嗪化合物可用作H4受体调节剂，并用于制备药物组合物和治疗由H4受体活性介导的疾病状态、障碍和病况，例如过敏、哮喘、自身免疫疾病和瘙痒症的方法。
• BIARYL DERIVATIVE AS GPR120 AGONIST
  申请人：LG Chem, Ltd.

  公开号：EP3239143A2

  公开（公告）日：2017-11-01

  The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

  本发明涉及一种由化学式1表示的生物芳基衍生物、生产该生物芳基衍生物的方法、包含该生物芳基衍生物的药物组合物以及该生物芳基衍生物的用途，由化学式1表示的生物芳基衍生物作为GPR120激动剂，促进胃肠道中GLP-1的生成、从巨噬细胞、胰腺细胞等的抗炎活性中降低肝脏、肌肉等的胰岛素抵抗，并可有效用于预防或治疗炎症或代谢性疾病，如糖尿病、糖尿病并发症、肥胖症、非酒精性脂肪肝、脂肪肝和骨质疏松症。
• Biaryl derivative as GPR120 agonist
  申请人：LG CHEM, LTD.

  公开号：US11261186B2

  公开（公告）日：2022-03-01

  Compounds having the chemical formula 1, a method for producing the compounds of chemical formula 1, a pharmaceutical composition comprising same, and use thereof as a GPR120 agonist for prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

  具有化学式1的化合物，制备所述化学式1化合物的方法，包含所述化合物的药物组合物，以及将其用作一种GPR120激动剂，用于预防或治疗炎症或代谢性疾病，如糖尿病、糖尿病并发症、肥胖症、非酒精性脂肪肝病、脂肪肝病和骨质疏松症。